Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.

Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression

Biogen

Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the Alzheimer's drug market after Lilly on Monday released more details on its late-stage trial of donanemab, Raymond James analysts wrote in a note late Monday. The overall safety and efficacy of donanemab appears similar to the Biogen and Eisai Co. Ltd.

Biogen, Eli Lilly likely to split the Alzheimer's drug market, analysts say

Eli Lilly and Company (NYSE:LLY ) 2023 AAIC Lilly Alzheimer's Disease Update Conference July 17, 2023 1:00 PM ET Company Participants Lauren Zierke - Executive Director of IR Daniel Skovronsky - Chief Scientific and Medical Officer Anne White - President, Lilly Neuroscience Mark Mintun - Group Vice President of Neuroscience Research and Development; President, Avid Radiopharmaceuticals John Sims - Head of Clinical Development for Donanemab Conference Call Participants Tim Anderson - Wolfe Research Alec Stranahan - Bank of America Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Seamus Fernandez - Guggenheim Evan Seigerman - BMO Colin Bristow - UBS Umer Raffat - Evercore Robyn Karnauskas - Truist Kerry Holford - Berenberg Andrew Baum - Citi Louise Chen - Cantor Trung Huynh - Credit Suisse Ladies and gentlemen, thank you for standing by, and welcome to the 2023 AAIC Lilly Alzheimer's Disease Update Conference Call. At this time, all participants are on a listen-only mode.

Eli Lilly and Company (LLY) 2023 AAIC Lilly Alzheimer's Disease Update Conference (Transcript)

Eli Lilly & Co revealed on Monday final results from its Phase 3 clinical study of donanemab at the Alzheimer's Association International Conference in Amsterdam, which showed that the antibody treatment slowed progression of early-stage Alzheimer's by about 35%. The pharmaceutical giant is seeking US Food and Drug Administration (FDA) approval for donanemab which, if granted, would be only the second Alzheimer's treatment to receive consent from the FDA after the agency recently approved Leqembi from Japanese drugmaker Eisai, the Associated Press (AP) reported.

Eli Lilly & Co study shows Alzheimer's drug slows memory decline

A Phase 3 trial shows that Eli Lilly's investigational Alzheimer's treatment donanemab significantly slowed cognitive and functional decline in people in the early stages of the disease.

Eli Lilly Says Alzheimer's Treatment Slows Cognitive Decline

For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.

Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio

Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.

Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year

Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year Additional subpopulation analyses presented live showed that those study participants at earliest stage of disease had even greater benefit, with 60% slowing of decline compared to placebo Furthermore, treatment effect continued to increase relative to placebo over the course of the trial, even though many participants completed their course of therapy at 6 or 12 months, supporting limited duration dosing FDA submission completed in Q2; regulatory action expected by end of year INDIANAPOLIS , July 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD). The data were shared at the 2023 Alzheimer's Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of the American Medical Association (JAMA).

Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA

The Eli Lilly and Co. LLY, -0.47% investigational Alzheimer's treatment donanemab has shown particular promise in treating patients at younger ages and in the earliest stage of disease, according to new late-stage trial results released Monday.

Eli Lilly's Alzheimer's treatment shows promise in early stages of disease — but safety concerns remain

Eli Lilly's experimental drug donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, the Alzheimer's Association said in a press release on Monday.

Lilly drug slows Alzheimer's by 60% for mildly impaired patients, Alzheimer's group says

Eli Lilly is adept at discovering and developing new medicines. The company's potential for innovation is bearing fruit.

Eli Lilly Stock: Bear Vs. Bull

A promising new Alzheimer's drug could spell "the beginning of the end" for the neurodegenerative disease.

New Alzheimer's drug could spell 'beginning of the end' for disease

Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesity drug market.

Eli Lilly Buys Versanis to Boost Its Obesity Drug Portfolio

Shares of Eli Lilly & Co (NYSE: LLY) gained nearly 4.0% today after the pharmaceutical behemoth said it will buy Versanis Bio for up to $1.925 billion. Other financial details are yet to be disclosed The aforementioned consideration includes both upfront payment and future instalments based on achieving certain milestones, as per the press release.

Eli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis Bio

Eli Lilly has agreed to buy privately owned Versanis Bio in a deal that could be worth up to $1.93 billion. Through this deal, Lilly will gain a novel mid-stage weight loss candidate known as bimagrumab.

Why Eli Lilly Stock Is Rising Today

Eli Lilly stock jumped Friday after unveiling a nearly $2 billion takeover that could bolster its efforts among weight-loss drugs.

Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss

The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk's Wegovy and Ozempic.

Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion

Eli Lilly (NYSE: LLY ) stock is a hot topic among traders on Friday after the company announced its acquisition of Versanis Bio . Versanis Bio is a clinical-stage biopharmaceutical company developing treatments for cardiometabolic diseases.

LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio

Eli Lilly and Co (NYSE:LLY) announced on Friday that it will buy privately held drug developer Versanis for up to $1.93 billion, in a bid to improve its portfolio of obesity drugs. Under the terms of the deal, Versanis shareholders could receive $1.93 billion in cash, which includes an upfront payment and subsequent payments upon achieving certain development and sales milestones.

Eli Lilly spends up to $1.93B to acquire obesity drug developer Versanis

Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are reached.

Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment

Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs.

Lilly to buy Versanis for up to $1.93 bln to boost obesity drug portfolio

Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic diseases, the companies said in a release Friday. Versanis is developing a monoclonal antibody called bimagrumab that is being studied alone and in combination with the popular weight-loss drug semaglutide to potentially further reduce fat mass while preserving muscle.

Eli Lilly to acquire Versanis Bio, expanding obesity-treatment pipeline

Medicxi co-led Company's US$70 million Series A less than 2 years ago Third Medicxi portfolio exit to US biopharma in last 12 months LONDON, GENEVA and JERSEY, British Isles, July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases, has entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones.

Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases

INDIANAPOLIS and NEW YORK , July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling.

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

Warren said the report shows that Congress needs to take additional steps to reduce the excessive prices of insulin from Eli Lilly, Sanofi and Novo Nordisk.

News for Eli Lilly Stock (LLY)